Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

Le Deley MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, Chompret A, Cayuela JM, Bayle C, Bernheim A, de Vathaire F, Vassal G, Hill C; Société Française d'Oncologie Pédiatrique.

J Clin Oncol. 2003 Mar 15;21(6):1074-81.

PMID:
12637473
2.

Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.

Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land VJ, Miser J, Shuster J, Vena D.

J Clin Oncol. 1999 Feb;17(2):569-77.

PMID:
10080601
3.

Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.

Hawkins MM, Wilson LM, Stovall MA, Marsden HB, Potok MH, Kingston JE, Chessells JM.

BMJ. 1992 Apr 11;304(6832):951-8.

4.

High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults.

Le Deley MC, Vassal G, Taïbi A, Shamsaldin A, Leblanc T, Hartmann O.

Pediatr Blood Cancer. 2005 Jul;45(1):25-31.

PMID:
15795880
5.

Role of radiation dose in the risk of secondary leukemia after a solid tumor in childhood treated between 1980 and 1999.

Allard A, Haddy N, Le Deley MC, Rubino C, Lassalle M, Samsaldin A, Quiniou E, Chompret A, Lefkopoulos D, Diallo I, de Vathaire F.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1474-82. doi: 10.1016/j.ijrobp.2009.09.032. Epub 2010 Mar 19.

PMID:
20303670
6.

Risk of Subsequent Leukemia After a Solid Tumor in Childhood: Impact of Bone Marrow Radiation Therapy and Chemotherapy.

Allodji RS, Schwartz B, Veres C, Haddy N, Rubino C, Le Deley MC, Labbé M, Diop F, Jackson A, Dayet F, Benabdennebi A, Llanas D, Vu Bezin J, Chavaudra J, Lefkopoulos D, Deutsch E, Oberlin O, de Vathaire F, Diallo I.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):658-67. doi: 10.1016/j.ijrobp.2015.07.2270. Epub 2015 Aug 7.

PMID:
26461008
7.

Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.

Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Fléchon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C.

J Clin Oncol. 1998 Oct;16(10):3386-91.

PMID:
9779717
8.

Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study.

Henderson TO, Rajaraman P, Stovall M, Constine LS, Olive A, Smith SA, Mertens A, Meadows A, Neglia JP, Hammond S, Whitton J, Inskip PD, Robison LL, Diller L.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):224-30. doi: 10.1016/j.ijrobp.2011.11.022. Epub 2012 Jul 14.

9.

Treatment-associated leukemia following testicular cancer.

Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, Curtis RE, Kohler BA, Wiklund T, Storm H, Holowaty E, Hall P, Pukkala E, Sleijfer DT, Clarke EA, Boice JD Jr, Stovall M, Gilbert E.

J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71.

PMID:
10904090
10.

Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood.

Le Vu B, de Vathaire F, Shamsaldin A, Hawkins MM, Grimaud E, Hardiman C, Diallo I, Vassal G, Bessa E, Campbell S, Panis X, Daly-Schveitzer N, Lagrange JL, Zucker JM, Eschwège F, Chavaudra J, Lemerle J.

Int J Cancer. 1998 Jul 29;77(3):370-7.

11.

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.

Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphaël M, Terrier-Lacombe MJ; Société Française d'Oncologie Pédiatrique.

Blood. 2001 Jun 1;97(11):3370-9.

12.

Incidence of second cancers in patients treated for Hodgkin's disease.

Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CT, Fuller LM, Mauch P, et al.

J Natl Cancer Inst. 1995 May 17;87(10):732-41.

PMID:
7563150
13.

Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.

Smith MA, Rubinstein L, Ungerleider RS.

Med Pediatr Oncol. 1994;23(2):86-98. Review.

PMID:
8202047
14.

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.

Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT, et al.

N Engl J Med. 1991 Dec 12;325(24):1682-7.

15.

The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.

Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.

Haematologica. 1998 Sep;83(9):812-23.

16.

Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A, Fung H, Bhatia R, Kashyap A, Molina A, O'Donnell MR, Parker PA, Sniecinski I, Snyder DS, Spielberger R, Stein A, Forman SJ.

Blood. 2000 Mar 1;95(5):1588-93.

17.

Etoposide and secondary haematological malignancies: coincidence or causality?

Zulian GB, Jotterand Bellomo M, Cabrol C, Beris P, Mermillod B, Alberto P.

Ann Oncol. 1993 Aug;4(7):559-66.

PMID:
8395872
18.

Risk of leukemia following treatment for non-Hodgkin's lymphoma.

Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, et al.

J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7.

PMID:
8089863
19.

Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.

Yagita M, Ieki Y, Onishi R, Huang CL, Adachi M, Horiike S, Konaka Y, Taki T, Miyake M.

Int J Oncol. 1998 Jul;13(1):91-6.

PMID:
9625808
20.

Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.

Smith MA, Rubinstein L, Cazenave L, Ungerleider RS, Maurer HM, Heyn R, Khan FM, Gehan E.

J Natl Cancer Inst. 1993 Apr 7;85(7):554-8.

PMID:
8455202

Supplemental Content

Support Center